Helix BioMedix, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HXBM research report →
Price Chart
About the company
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company was founded in 1988 and is headquartered in Bothell, WA.
- CEO
- Robin L. Carmichael
- IPO
- 1999
- Employees
- 8
- HQ
- Bothell, WA, US
Get TickerSpark's AI analysis on HXBM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $739.29K
- P/E
- -1.34
- PEG
- -0.01
- P/S
- 0.92
- P/B
- 0.48
- EV/EBITDA
- 0.97
- Div Yield
- 0.00%
- Gross Margin
- 99.36%
- Op Margin
- -73.81%
- Net Margin
- -68.32%
- ROE
- -30.45%
- ROIC
- -38.72%
Latest fiscal year · YoY change
- Revenue
- $807.19K+0.4%
- Gross Profit
- $802.01K+0.5%
- Op Income
- $-595,812
- Net Income
- $-551,512+43.9%
- EPS
- $-2.45+43.9%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $6.50
- 52W Low
- $1.00
- 50D MA
- $3.41
- 200D MA
- $2.14
- Beta
- 1.37
- RSI (14)
- 37
- Avg Volume
- 126
No earnings-call transcripts are available for HXBM yet.
- Free Float
- 44.4%
- Shares Outstanding
- 224.71K
- Float Shares
- 99.74K
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 26, 03 | BEATTY R STEPHEN | buy | 60,000 |
| Dec 26, 03 | BEATTY R STEPHEN | other | 25,000 |
| Dec 26, 03 | BEATTY R STEPHEN | other | 60,000 |
| Dec 26, 03 | BEATTY R STEPHEN | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HXBM coverage
Recent articles, reports, and earnings notes.
No research on HXBM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HXBM report →